Cardiff Oncology (CRDF) to Release Earnings on Thursday

Cardiff Oncology (NASDAQ:CRDF) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.20) per share and revenue of $0.09 million for the quarter.

Cardiff Oncology Stock Down 5.8 %

Shares of NASDAQ CRDF opened at $2.78 on Wednesday. The stock’s 50 day moving average price is $3.39 and its two-hundred day moving average price is $3.48. Cardiff Oncology has a 52-week low of $2.01 and a 52-week high of $5.64. The stock has a market capitalization of $184.94 million, a P/E ratio of -2.96 and a beta of 1.74.

Wall Street Analyst Weigh In

Separately, HC Wainwright upped their price objective on Cardiff Oncology from $13.00 to $17.00 and gave the company a “buy” rating in a research note on Friday, February 28th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.